Skip to main content

Table 1 Characteristics of the included studies

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Study Phase Number of patient Treatment regimens Median follow-up
Time(M) 		Primary
endpoint 		Median
PFS(M) 		PFS rate Median
treatment
Time(M)
Dimopoulos(2016)
POLLUX
Dimopoulos(2018)
POLLUX 		III 569 T:daratumumab16mg/kg + lenalidomide25mg + dexamethasone40mg
C:lenalidomide25mg + dexamethasone40mg 		T:13.5
C:13.5
T:25.4
C:25.4 		PFS T:N
C:18.4
T:N
C:17.5 		12 Months
T:83.2%C:60.1%
24 Months
T:68.0%C:40.9% 		T:24.5
C:16.0
Palumbo(2016)
CASTOR
Palumbo(2018)
CASTOR 		III 498 T:daratumumab 16 mg/kg
+bortezomib1.3 mg/m2 + dexamethasone20mg
C:bortezomib1.3 mg/m2 + dexamethasone20mg 		T:7.4
C:7.4
T:19.4
C:19.4 		PFS T:N
C:7.2
T:16.7
C:7.1 		12 Months
T:60.7%C:26.9%
18 Months
T:48% C:7.9% 		T:13.4
C:5.2
Facon(2019)
NCT02252172 		III 737 T:daratumumab16mg/kg + lenalidomide25mg + dexamethasone40mg
C:lenalidomide25mg + dexamethasone40mg 		T:28
C:28 		PFS T:N
C:31.9 		30 months
T:N
C:N 		T:25.3
C:21.3
Mateos(2017)
ALCYONE
Maria(2019)
ALCYONE 		III 706 T:daratumumab16mg/kg + bortezomib1.3 mg/m2 + melphalan9mg/m2 + prednisone 60 mg/m2
C:bortezomib1.3 mg/m2 + melphalan9mg/m2 + prednisone 60 mg/m2 		T:16.5
C:16.5
T:40.1
C:40.1 		PFS T:N
C:18.1
T:36.4
C:19.3 		18 months
T:71.6%C:50.2%
36 months
T:50.7%C:18.5% 		T:14.7
C:12
Michel (2019)
ICARIA-MM 		III 307 T:isatuximab10mg/kg + pomalidomide4mg + dexamethasone 40 mg
C:pomalidomide4mg + dexamethasone40mg 		T:11.6
C:11.6 		PFS T:11.5
C:6.5 		T:N
C:N 		T:9.6
C:5.6
Philippe (2019)
CASSIOPEIA 		III 1085 T:daratumumab16mg/kg + bortezomib1.3 mg/m2 + thalidomide100mg + dexamethasone40mg
C:bortezomib1.3 mg/m2 + thalidomide100mg + dexamethasone40mg 		T:18.8
C:18.8 		SCR T:N
C:N 		T:N
C:N 		T:8.9
C:8.7
Mateos(2019)
KEYNOTE-183 		III 249 T: pembrolizumab 200 mg
+pomalidomide 4 mg + dexamethasone40mg
C:pomalidomide 4 mg + dexamethasone40mg 		T:8.1
C:8.1 		PFS
OS 		T:5.6
C:8.4 		6 months
T:48%
C:60% 		T:4.1
C:4.2
Usmani(2019)
KEYNOTE-185 		III 301 T:pembrolizumab200mg + lenalidomide25mg + dexamethasone40mg
C:+lenalidomide25mg + dexamethasone40mg 		T:6.6
C:6.6 		PFS T:N
C:N 		6 months
T:82%
C:85% 		T:4.4
C:N
Andrzej(2016)
NCT01478048 		II 152 T:Elotuzumab10mg/kg + bortezomib1.3 mg/m2 + dexamethasone20mg
C:bortezomib1.3 mg/m2 + dexamethasone20mg 		T:15.9
C:11.7 		PFS T:9.7
C:6.9 		24 months
T:18%
C:11% 		T:N
C:N
Meletios(2018)
ELOQUENT-3 		II 117 T:Elotuzumab10-20 mg/kg + pomalidomide4mg
+ dexamethasone40mg
C:pomalidomide4mg + dexamethasone40mg 		T:9.1
C:9.1 		PFS T:10.3
C:4.7 		T:N
C:N 		T:8.4
C:4.7
Sagar(2015)
ELOQUENT-2
Dimopoulos(2018)
ELOQUENT-2 		III 646 T:Elotuzumab10mg/kg
+lenalidomide25mg + dexamethasone40mg
C:lenalidomide25mg + dexamethasone40mg 		T:24.5
C:24.5
T:46
C:48 		PFS
ORR 		T: 19.4
C:14.9
T:N
C:N 		12 months
T:68%C:57%
24 months
T:41%C:27%
48 months
T:21%C:14% 		T: 19
C:14
  1. Abbreviations: PFS progression-free survival, ORR overall response rate, SCR stringent complete response, N not available/reached, T trail, C control, M month
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us